Review: Treatment of Helicobacter pylori Infection 2019.
clarithromycin
dual therapy
proton-pump inhibitor
quadruple therapy
triple therapy
vonoprazan
Journal
Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
accepted:
08
07
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
1
1
2020
Statut:
ppublish
Résumé
This review summarizes important studies regarding Helicobacter pylori therapy published from May 2018 to May 2019. The main themes that emerge involve studies assessing the efficacy of bismuth-based regimens. While in recent years the efficacy of bismuth-based quadruple therapy as a second-line therapy has been clearly established, there is now substantial evidence that it is the best performing first-line therapy. Antibiotic resistance was again intensely studied this year, and a clear and dramatic increase in resistance is noted for clarithromycin and levofloxacin; most notably, it may not be possible to support these therapies in most regions of the world much longer without testing. The utility of vonoprazan as an alternative to proton-pump inhibitor therapy, especially in resistant and difficult to treat groups, has also been considered in greater detail this year, as well as means of supporting and enhancing adherence to therapy. Several studies showed that the diversity of gut microbiota was significantly altered shortly after H pylori eradication. However, the diversity was restored to pre-treatment state after 2 months in patients treated with triple therapy. More studies are warranted to assess the long-term changes of gut microbiota after H pylori eradication.
Substances chimiques
Anti-Bacterial Agents
0
Proton Pump Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12640Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Muñoz N, Sánchez-Delgado J, Baylina M, et al. Systematic review, meta-analysis, and meta-regression: successful second-line treatment for Helicobacter pylori. Helicobacter. 2018;23(3):e12488.
Yeo YH, Hsu CC, Lee CC, et al. Systematic review and network meta-analysis: comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019;34(1):59-67.
Lee SM, Park SY, Kim MJ, et al. Key lime (Citrus aurantifolia) inhibits the growth of triple drug resistant Helicobacter pylori. Gut Pathog. 2018;10:16.
Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In vitro activity of 3-bromopyruvate, an anticancer compound, against antibiotic-susceptible and antibiotic-resistant Helicobacter pylori strains. Cancers (Basel). 2019;11(2):229.
Nagata Y, Nagasaka K, Koyama S, et al. Successful eradication of Helicobacter pylori with a herbal medicine, goshuyuto (Wu Zhu Yu Tang), plus rabeprazole after failure of triplet therapy with vonoprazan: a report of three cases. J Dig Dis. 2018;19(7):439-442.
Fontes LES, Martimbianco ALC, Zanin C, Riera R. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2019;2:CD012357.
Tai WC, Liang CM, Kuo CM, et al. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74:1718-1724.
Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(7):e14396.
Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66:6-30.
Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24(7):538-543.
Kabakambira JD, Hategeka C, Page C, et al. Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial. BMC Gastroenterol. 2018;18(1):134.
Sezgin O, Aydın MK, Özdemir AA, Kanık AE. Standard triple therapy in Helicobacter pylori eradication in Turkey: systematic evaluation and meta-analysis of 10-year studies. Turk J Gastroenterol. 2019;30(5):420-435.
Leow AH, Azmi AN, Loke MF, Vadivelu J, Graham DY, Goh KL. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: prolonging treatment or adding bismuth: which is better? J Dig Dis. 2018;19(11):674-677.
Shahbazi S, Vahdat Shariatpanahi Z. Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: a randomized controlled trial. Indian J Gastroenterol. 2018;37(6):550-554.
Chen MJ, Chen CC, Chen YN, et al. Systematic review with meta-analysis: concomitant therapy vs. triple therapy for the first-line treatment of Helicobacter pylori infection. Am J Gastroenterol. 2018;113(10):1444-1457.
Hsu PI, Tsay FW, Graham DY, et al. Equivalent efficacies of reverse hybrid and bismuth quadruple therapies in eradication of Helicobacter pylori infection in a randomized controlled trial. Clin Gastroenterol Hepatol. 2018;16(9):1427-1433.
Macías-García F, Bastón-Rey I, de la Iglesia-García D, Calviño-Suárez C, Nieto-García L, Domínguez-Muñoz JE. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter pylori infection in an area of high resistance to clarithromycin: a prospective, cross-sectional, comparative, open trial. Helicobacter. 2019;24(1):e12546.
Huang HT, Wang HM, Yang SC, et al. Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication. Infect Drug Resist. 2018;11:2073-2080.
Gatta L, Scarpignato C, Fiorini G, et al. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther. 2018;47(9):1261-1269.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-1382.e17.
Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24(7):780.e5-780.e8.
Fiorini G, Zullo A, Saracino IM, Pavoni M, Vaira D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016. Scand J Gastroenterol. 2018;53(6):661-664.
Bachir M, Allem R, Benejat L, et al. Molecular detection of mutations involved in Helicobacter pylori antibiotic resistance in Algeria. J Antimicrob Chemother. 2018;73(8):2034-2038.
Lopo I, Libânio D, Pita I, Dinis-Ribeiro M, Pimentel-Nunes P. Helicobacter pylori antibiotic resistance in Portugal: systematic review and meta-analysis. Helicobacter. 2018;23(4):e12493.
Gonzalez-Hormazabal P, Musleh M, Escandar S, et al. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. BMC Gastroenterol. 2018;18(1):91.
Mosites E, Bruden D, Morris J, et al. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. J Glob Antimicrob Resist. 2018;15:148-153.
Saniee P, Hosseini F, Kadkhodaei S, Siavoshi F, Khalili-Samani S. Helicobacter pylori multidrug resistance due to misuse of antibiotics in Iran. Arch Iran Med. 2018;21(7):283-288.
Khien VV, Thang DM, Hai TM, et al. Management of antibiotic-resistant Helicobacter pylori infection: perspectives from Vietnam. Gut Liv. 2019. https://doi.org/10.5009/gnl18137. [Epub ahead of print].
Kageyama C, Sato M, Sakae H, et al. Increase in antibiotic resistant Helicobacter pylori in a university hospital in Japan. Infect Drug Resist. 2019;12:597-602.
Zhang XY, Shen WX, Chen CF, et al. Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real-time PCR. Cancer Med. 2019;8(4):1633-1640.
Bińkowska A, Biernat MM, Łaczmański Ł, Gościniak G. Genetic determinants and prediction of antibiotic resistance phenotypes in Helicobacter pylori. Front Microbiol. 2018;9:3154.
Lee JW, Kim N, Nam RH, et al. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24(2):e12561.
Blümel B, Goelz H, Kist M, Glocker EO. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter. 2018;23(4):e12494.
Liou JM, Chen PY, Luo JC, et al. Efficacies of genotypic resistance-guided vs empirical therapy for refractory Helicobacter pylori infection. Gastroenterology. 2018;155(4):1109-1119.
Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter. 2019;24:e12584.
Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49:1385-1394.
Gan HY, Peng TL, Huang YM, et al. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: a prospective, single-center, randomized clinical trial. Sci Rep. 2018;8(1):9045.
Hajiani E, Alavinejad P, Avandi N, Masjedizadeh AR, Shayesteh AA. Comparison of levofloxacin-based, 10-day sequential therapy with 14-day quadruple therapy for Helicobacter pylori eradication: a randomized clinical trial. Middle East J Dig Dis. 2018;10(4):242-248.
Ladrón-de-Guevara L, Bornstein-Quevedo L, González-Huezo S, Castañeda-Romero B, Costa FG, di Silvio-López M. Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: results from an open-label, randomized, noninferiority phase iiib trial. Rev Gastroenterol Mex. 2018. pii: S0375-0906(18)30132-0. https://doi.org/10.1016/j.rgmx.2018.04.005. [Epub ahead of print].
Latif S, Akther N, Amjed S, et al. Efficacy of standard triple therapy versus levofloxacin based alternate therapy against Helicobacter pylori infection. J Pak Med Assoc. 2018;68(9):1295-1299.
Sue S, Shibata W, Sasaki T, et al. Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori. J Gastroenterol Hepatol. 2019;34(4):686-692.
Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study. J Antimicrob Chemother. 2019;74(4):1069-1077.
McNicholl AG, Bordin DS, Lucendo A, et al. Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol 2019. pii: S1542-3565(19)30369-6. [Epub ahead of print].
McNicholl AG, O'Morain CA, Megraud F, Gisbert JP. Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg). Helicobacter. 2019; [Epub ahead of print].
Guo T, Wang Q, Wu X, et al. Amoxicillin-clarithromycin-containing bismuth quadruple therapy for primary eradication of Helicobacter pylori. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019;41(1):75-79.
Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. J Antimicrob Chemother. 2018;73(6):1681-1687.
Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. Eur J Gastroenterol Hepatol. 2018;30(6):621-625.
Chen L, He J, Wang L, et al. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med. 2018;18(4):569-576.
Xie Y, Zhu Z, Wang J, Zhang L, Zhang Z, Lu H. Ten-day quadruple therapy comprising low-dose rabeprazole, bismuth, amoxicillin, and tetracycline is an effective and safe first-line treatment for Helicobacter pylori infection in a population with high antibiotic resistance: a prospective, multicenter, randomized, parallel-controlled clinical trial in China. Antimicrob Agents Chemother. 2018;62(9):e00432-18.
Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P. Efficacy and tolerability of two quadruple regimens: bismuth, omeprazole, metronidazole with amoxicillin or tetracycline as first-line treatment for eradication of Helicobacter pylori in patients with duodenal ulcer: a randomized clinical trial. PLoS One. 2018;13(6):e0197096.
Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23(3):e12485.
Zagari RM, Romiti A, Ierardi E, et al. The “three-in-one” formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: efficacy and safety in daily clinical practice. Helicobacter. 2018;23(4):e12502.
Agudo-Fernández S, González Blanco A. Retrospective analysis of the use of quadruple therapy with bismuth (Pylera®) in real-life clinical practice in Spain. Gastroenterol Hepatol. 2018;41(8):483-489.
Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24(2):e12570.
Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter. 2019;24(2):e12565.
Kim SE, Roh JH, Park MI, et al. Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line Helicobacter pylori eradication therapy. Korean J Gastroenterol. 2019;73(1):26-34.
Lee JW, Kim N, Nam RH, et al. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2019;34(4):666-672.
Miftahussurur M, Aftab H, Shrestha PK, et al. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control. 2019;8:40.
Miftahussurur M, Cruz M, Doohan D, et al. Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic. PLoS One. 2019;14(3):e0213868.
Ribaldone DG, Fagoonee S, Astegiano M, et al. Rifabutin-based Rescue therapy for Helicobacter pylori eradication: a long-term prospective study in a large cohort of difficult-to-treat patients. J Clin Med. 2019;8(2):pii: E199.
Nam JH, Ryu KH, Park BJ, Lee CW, Park EC. Rate and predictive factors of Helicobacter pylori recurrence: analysis of a screening cohort. Saudi J Gastroenterol. 2019. https://doi.org/10.4103/sjg.sjg_456_18. [Epub ahead of print].
Choi YK, Ahn JY, Won SH, et al. Eradication rate of Helicobacter pylori reinfection in Korea: a retrospective study. J Gastroenterol Hepatol. 2019. https://doi.org/10.1111/jgh.14639. [Epub ahead of print].
McNicholl AG, Molina-Infante J, Lucendo AJ, et al. Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: a randomized, double-blind, placebo-controlled trial. Helicobacter. 2018;23(5):e12529.
Zhu XY, Du J, Zhao WJ, et al. Influence of two kinds of probiotics combined with bismuth quadruple therapy for Helicobacter pylori eradication. Zhonghua Yi Xue Za Zhi. 2018;98(28):2246-2249.
Dore MP, Bibbò S, Pes GM, Francavilla R, Graham DY. Role of probiotics in Helicobacter pylori eradication: lessons from a study of Lactobacillus reuteri strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a proton-pump inhibitor. Can J Infect Dis Med Microbiol. 2019;2019:3409820.
Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. https://doi.org/10.1097/MD.0000000000015180.
Tanabe H, Yoshino K, Ando K, et al. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob. 2018;17(1):29.
Mori N, Nishiura Y, Suga D, et al. Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori. Biomed Rep. 2018;9(2):169-174.
Saito Y, Konno K, Sato M, et al. Vonoprazan-based third-line therapy has a higher eradication rate against sitafloxacin-resistant Helicobacter pylori. Cancers (Basel). 2019;11(1):pii: E116.
Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23(4):e12495.
Sunwoo J, Oh J, Moon SJ, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018;48(2):206-218.
Cheng HC, Liou JM, Luo JC, et al. The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus. Helicobacter. 2018;23(5):e12533.
Seko T, Tachi T, Hatakeyama H, Noguchi Y, Teramachi H. Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in Helicobacter pylori eradication therapy. Int J Clin Pract. 2019;73:e13349.
Boltin D, Dotan I, Birkenfeld S. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Ann Gastroenterol. 2019;32(1):52-59.
Wang T, Yang X, Li Y, et al. Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: a prospective randomized controlled study. Helicobacter. 2019;24(3):e12569.
Jakobsson HE, Jernberg C, Andersson AF, Sjölund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5:e9836.
Yap TW, Gan HM, Lee YP, et al. Helicobacter pylori eradication causes perturbation of the human gut microbiome in young adults. PLoS One. 2016;11:e0151893.
Oh B, Kim BS, Kim JW, et al. The effect of probiotics on gut microbiota during the Helicobacter pylori eradication: randomized controlled trial. Helicobacter. 2016;21:165-174.
Yanagi H, Tsuda A, Matsushima M, et al. Changes in the gut microbiota composition and the plasma ghrelin level in patients with Helicobacter pylori-infected patients with eradication therapy. BMJ Open Gastroenterol. 2017;4:e000182.
Hsu PI, Pan CY, Kao JY, et al. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of proteobacteria and decreased relative abundances of bacteroidetes and actinobacteria. Helicobacter. 2018;23:e12498.
Chen L, Xu W, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: an open-label, randomized clinical trial. EBioMedicine. 2018;35:87-96.
Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication - a multicentre randomised trial. Lancet Infect Dis. Gut 2019;68:A5-A6.
Coelho LGV, Marinho JR, Genta R, et al. IVth Brazilian consensus conference on Helicobacter pylori infection. Arq Gastroenterol. 2018;55(2):97-121.